Summary: Exenatide, an injectable peptide currently in phase two clinical trials for treating type 2 diabetes, reduces symptoms of Idiopathic Intercranial Hypertension blinding headaches, a new study reports. Source: University of Birmingham Patients with ‘blinding’ headaches known as Idiopathic Intercranial Hypertension (IIH) could be treated with an injectable peptide used for type 2 diabetes, a new trial...
